Why Codexis Shares Are Slumping Today

• Codexis Inc (NASDAQ: CDXS) expects Q2 sales of approximately $38 million and FY22 sales of 135 million to $141 million, below the prior expectation of $152 million - $158 million.

• FY22 product revenues are expected to be $112 million - $118 million, consistent with prior guidance. However, product revenues from Pfizer Inc (NYSE: PFE) are now expected to be at the low end of previous guidance of $75 million - $80 million, expected to be offset by revenues from other customers.

• Gross margin on product revenue is expected to be 65% to 70%, consistent with prior view.

• "Our prior total revenue guidance for 2022 anticipated more R&D revenue from these partnerships in 2022 than we believe now possible at this point in the year due to a mix of fewer new deals being signed in 2022 and lower-than-anticipated revenue from existing customers," said CEO John Nicols.

• The Q2 earnings release is scheduled for August 4.

• Separately, Codexis agreed with Pfizer to supply an enzyme used to manufacture a critical intermediate for nirmatrelvir, an active pharmaceutical ingredient in Paxlovid, Pfizer's flagship antiviral for COVID-19.

• Pfizer will pay Codexis a retainer fee of $25.9 million in lieu of existing orders for delivery of the Enzyme in early 2023, which have been canceled.

• Price Action: CDXS shares traded lower by 23.86% at $9.19 in premarket on the last check Friday.

See more from Benzinga

• Read Why Pfizer's Hospira Is Recalling One Lot Of Propofol Injectable Emulsion

• AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, In Expert Review

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.